{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T20:26:27Z","timestamp":1785183987598,"version":"3.55.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"am","delay-in-days":315,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007412","name":"Nippon Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007533","name":"Kobayashi Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007533","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004398","name":"Mitsubishi Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004398","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.canlet.2024.217220","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T13:27:36Z","timestamp":1725629256000},"page":"217220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer"],"prefix":"10.1016","volume":"604","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3450-1628","authenticated-orcid":false,"given":"Xinzhao","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Uchibori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3899-8713","authenticated-orcid":false,"given":"Nobuyuki","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Utsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Takemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumie","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9749-1034","authenticated-orcid":false,"given":"Satoshi","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Yanagitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-895X","authenticated-orcid":false,"given":"Ryohei","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2024.217220_bib1","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.canlet.2024.217220_bib2","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3389\/fphys.2019.00216","article-title":"Discovery stories of RET fusions in lung cancer: a mini-review","volume":"10","author":"Takeuchi","year":"2019","journal-title":"Front. Physiol."},{"issue":"1","key":"10.1016\/j.canlet.2024.217220_bib3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jtho.2017.10.021","article-title":"Clinical and translational implications of RET rearrangements in non-small cell lung cancer","volume":"13","author":"Ferrara","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.canlet.2024.217220_bib4","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1158\/2159-8290.CD-13-0035","article-title":"Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas","volume":"3","author":"Drilon","year":"2013","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.canlet.2024.217220_bib5","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(16)30562-9","article-title":"Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial","volume":"17","author":"Drilon","year":"2016","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2024.217220_bib6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S2213-2600(16)30322-8","article-title":"Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial","volume":"5","author":"Yoh","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.canlet.2024.217220_bib7","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer","author":"Hadoux","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.canlet.2024.217220_bib8","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study","volume":"22","author":"Gainor","year":"2021","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2024.217220_bib9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41698-021-00188-x","article-title":"The L730V\/I RET roof mutations display different activities toward pralsetinib and selpercatinib","volume":"5","author":"Shen","year":"2021","journal-title":"npj Precis. Oncol."},{"issue":"4","key":"10.1016\/j.canlet.2024.217220_bib10","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jtho.2020.01.006","article-title":"RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies","volume":"15","author":"Solomon","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.canlet.2024.217220_bib11","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.annonc.2020.10.002","article-title":"Defining resistance mechanisms to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer","volume":"31","author":"Tan","year":"2020","journal-title":"Ann. Oncol. : Offic. J. Eur. Soc. Med. Oncol."},{"issue":"294","key":"10.1016\/j.canlet.2024.217220_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004652","article-title":"Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer","volume":"6","author":"Niederst","year":"2013","journal-title":"Sci. Signal."},{"issue":"1","key":"10.1016\/j.canlet.2024.217220_bib13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.21037\/atm.2016.12.09","article-title":"MET\/HGF pathway activation as a paradigm of resistance to targeted therapies","volume":"5","author":"Ko","year":"2017","journal-title":"Ann. Transl. Med."},{"issue":"11","key":"10.1016\/j.canlet.2024.217220_bib14","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1111\/cas.15529","article-title":"Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer","volume":"113","author":"Sakashita","year":"2022","journal-title":"Cancer Sci."},{"issue":"6","key":"10.1016\/j.canlet.2024.217220_bib15","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.21037\/tcr.2019.09.61","article-title":"Blockade of AXL activation overcomes acquired resistance to EGFR tyrosine kinase inhibition in non-small cell lung cancer","volume":"8","author":"Wang","year":"2019","journal-title":"Transl. Cancer Res."},{"issue":"10","key":"10.1016\/j.canlet.2024.217220_bib16","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/2159-8290.CD-12-0108","article-title":"HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation","volume":"2","author":"Takezawa","year":"2012","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.canlet.2024.217220_bib17","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.cell.2012.10.035","article-title":"MED12 controls the response to multiple cancer drugs through regulation of TGF-\u03b2 receptor signaling","volume":"151","author":"Huang","year":"2012","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.canlet.2024.217220_bib18","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/s41467-022-28848-x","article-title":"The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers","volume":"13","author":"Rosen","year":"2022","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.canlet.2024.217220_bib19","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1177\/1087057117696795","article-title":"Three-dimensional cell cultures in drug discovery and development [published correction appears in SLAS discov. 2021 oct;26(9):NP1]","volume":"22","author":"Fang","year":"2017","journal-title":"SLAS Discov."},{"issue":"3","key":"10.1016\/j.canlet.2024.217220_bib20","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.bbrc.2020.08.075","article-title":"Differences in drug sensitivity between two-dimensional and three-dimensional culture systems in triple-negative breast cancer cell lines","volume":"533","author":"Muguruma","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2024.217220_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.614096","article-title":"Three-dimensional ex vivo culture for drug responses of patient-derived gastric cancer tissue","volume":"10","author":"Chen","year":"2021","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2024.217220_bib22","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.bbrc.2018.05.031","article-title":"3D culture system containing gellan gum restores oncogene dependence in ROS1 rearrangements non-small cell lung cancer","volume":"501","author":"Gong","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"10","key":"10.1016\/j.canlet.2024.217220_bib23","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1111\/1750-3841.15887","article-title":"Molecular weight effects of low acyl gellan gum on antioxidant capacity and rheological properties","volume":"86","author":"Baawad","year":"2021","journal-title":"J. Food Sci."},{"key":"10.1016\/j.canlet.2024.217220_bib24","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat. Protoc."},{"issue":"6166","key":"10.1016\/j.canlet.2024.217220_bib25","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1247005","article-title":"Genome-scale CRISPR-Cas9 knockout screening in human cells","volume":"343","author":"Shalem","year":"2014","journal-title":"Science"},{"issue":"24","key":"10.1016\/j.canlet.2024.217220_bib26","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1158\/0008-5472.CAN-23-1127","article-title":"CRISPR screening identifies mechanisms of resistance to KRASG12C and SHP2 inhibitor combinations in non-small cell lung cancer","volume":"83","author":"Prahallad","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.217220_bib27","doi-asserted-by":"crossref","first-page":"6399","DOI":"10.1038\/s41388-019-0887-2","article-title":"Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer","volume":"38","author":"Raoof","year":"2019","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.canlet.2024.217220_bib28","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1097\/JTO.0b013e3182721ed1","article-title":"Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2\/ad","volume":"7","author":"Matsubara","year":"2012","journal-title":"J. Thorac. Oncol. : official publication of the International Association for the Study of Lung Cancer"},{"issue":"6","key":"10.1016\/j.canlet.2024.217220_bib29","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1124\/molpharm.120.000207","article-title":"Novel human-derived RET fusion NSCLC cell lines have heterogeneous responses to REoffic. Publ. Int. Assoc. Stud. Lung CancerT inhibitors and differential regulation of downstream signaling","volume":"99","author":"Schubert","year":"2021","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.canlet.2024.217220_bib30","article-title":"D898_E901 RET deletion is oncogenic, responds to selpercatinib, and treatment resistance can arise via RET-independent mechanisms","volume":"7","author":"Porcelli","year":"2023","journal-title":"JCO Precis. Oncol."},{"issue":"8","key":"10.1016\/j.canlet.2024.217220_bib31","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","article-title":"Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management [published correction appears in Nat Rev Clin Oncol. 2022 Nov;19(11):744]","volume":"19","author":"Cooper","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.217220_bib32","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/jhg.2010.12","article-title":"A functional epidermal growth factor (EGF) polymorphism, EGF serum levels and renal cell carcinoma risk in a Chinese population","volume":"55","author":"Zhu","year":"2010","journal-title":"J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.canlet.2024.217220_bib33","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0009-8981(86)90118-X","article-title":"Physiological concentrations of human epidermal growth factor in biological fluids: use of a sensitive enzyme immunoassay","volume":"158","author":"Joh","year":"1986","journal-title":"Clin. Chim. Acta"},{"issue":"6","key":"10.1016\/j.canlet.2024.217220_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0252646","article-title":"Epidermal growth factor as a potential prognostic and predictive biomarker of response to platinum-based chemotherapy","volume":"16","author":"Geens","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2024.217220_bib35","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.canlet.2019.10.033","article-title":"Targeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium","volume":"469","author":"Guo","year":"2020","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.canlet.2024.217220_bib36","first-page":"127","article-title":"Serum levels of transforming growth factor alpha in gastrointestinal cancer patients","volume":"4","author":"Moskal","year":"1995","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"4","key":"10.1016\/j.canlet.2024.217220_bib37","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1478-3231.1999.tb00056.x","article-title":"Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma","volume":"19","author":"Harada","year":"1999","journal-title":"Liver"},{"key":"10.1016\/j.canlet.2024.217220_bib38","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41392-022-01168-8","article-title":"Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective","volume":"7","author":"Yang","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"5","key":"10.1016\/j.canlet.2024.217220_bib39","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1158\/2159-8290.CD-15-0336","article-title":"Understanding the MIG6-EGFR signaling Axis in lung tumorigenesis","volume":"5","author":"Izumchenko","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2024.217220_bib40","article-title":"MIG6 mediates adaptive and acquired resistance to ALK\/ROS1 fusion kinase inhibition through EGFR bypass signaling","volume":"26","author":"Chen","year":"2023","journal-title":"Mol. Cancer Therapeut."},{"issue":"24","key":"10.1016\/j.canlet.2024.217220_bib41","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.173688","article-title":"MIG6 loss confers resistance to ALK\/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF","volume":"8","author":"Kondo","year":"2023","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.canlet.2024.217220_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068966","article-title":"The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors","volume":"8","author":"Chang","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.canlet.2024.217220_bib43","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","article-title":"Combined BRAF, EGFR, and MEK inhibition in patients with BRAFV600E-mutant colorectal cancer","volume":"8","author":"Corcoran","year":"2018","journal-title":"Cancer Discov."},{"issue":"Issue 2","key":"10.1016\/j.canlet.2024.217220_bib44","article-title":"Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial","volume":"28","author":"Lee","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2024.217220_bib45","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1038\/s41467-018-07341-4","article-title":"RET rearrangements are actionable alterations in breast cancer","volume":"9","author":"Paratala","year":"2018","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.canlet.2024.217220_bib46","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nm.2644","article-title":"KIF5B-RET fusions in lung adenocarcinoma","volume":"18","author":"Kohno","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2024.217220_bib47","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13000-015-0368-z","article-title":"KIF5B-RET Fusion gene may coincide oncogenic mutations of EGFR or KRAS gene in lung adenocarcinomas","volume":"10","author":"Kim","year":"2015","journal-title":"Diagn. Pathol."},{"issue":"1","key":"10.1016\/j.canlet.2024.217220_bib48","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1186\/s12967-022-03593-3","article-title":"RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer","volume":"20","author":"Wang","year":"2022","journal-title":"J. Transl. Med."},{"issue":"10","key":"10.1016\/j.canlet.2024.217220_bib49","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1016\/j.celrep.2017.08.037","article-title":"KIF5B-RET oncoprotein signals through a multi-kinase signaling hub","volume":"20","author":"Das","year":"2017","journal-title":"Cell Rep."},{"issue":"13 Mar","key":"10.1016\/j.canlet.2024.217220_bib50","article-title":"Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer","volume":"8","author":"Uchibori","year":"2017","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.canlet.2024.217220_bib51","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41568-020-00302-4","article-title":"Non-genetic mechanisms of therapeutic resistance in cancer","volume":"20","author":"Marine","year":"2020","journal-title":"Nat. Rev. Cancer"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524006153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524006153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T04:57:32Z","timestamp":1730869052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524006153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":51,"alternative-id":["S0304383524006153"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.217220","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.217220","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"217220"}}